Dr Ruth Crystal September 2, 2023 COVID Newsletter

"Molnupiravir [is] used during acute #COVID infections to decrease COVID hospitalizations & deaths...large randomized controlled...study that [it] does not decrease COVID hospitalizations or deaths.

We also know that #Molnupiravir ... can lead to hundreds of SARS-CoV-2 mutations in immunocompromised patients, potentially generating new variants.

A new study shows that in countries that prescribe Molnupiravir, there are many more...mutations. The increase in...mutations is related to how many prescriptions for Molnupiravir were given in each country. In Canada, Netherlands, France & Sweden, [it] is not available. These countries have the fewest...viral mutations...In contrast, Australia has the highest number of Molnupiravir prescriptions & they also have the highest amount of...mutations...

I believe that Molnupiravir should be recalled since it does not prevent hospitalizations & deaths, & it increases mutations in the virus"

https://drruth.substack.com/p/covid-news-and-more-9223

Cox, R.M., Lieber, C.M., Wolf, J.D. et al. Comparing #molnupiravir and #nirmatrelvir/ritonavir #efficacy and the effects on #SARS-CoV-2 #transmission in animal #models. Nat Commun 14, 4731 (2023). https://doi.org/10.1038/s41467-023-40556-8 #research #science #antivirals #prophylaxis

@Nature Ensitrelvir treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of #ensitrelvir-resistant #SarsCoV2 variants to guide antiviral treatment selection.
In vitro and in vivo characterization of #SarsCoV2 resistance to #ensitrelvir
https://www.nature.com/articles/s41467-023-40018-1

''#Ensitrelvir #treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of ensitrelvir-resistant SARS-CoV-2 variants to guide antiviral treatment selection.''

Possible Intended Use For Molnupiravir Bioavailable Protease Inhibitor -

Dr Ariyana Love - Rumble Channel -
https://rumble.com/user/DrAriyanaLove
__
Lou Corona - Enzyme Deficiency, Putrification, Rancidification & Fermentation -
https://m.youtube.com/watch?v=oaZaESj5_zA
__
Parasites in Food: From a Neglected Position to an Emerging Issue - PMC -
https://archive.ph/BWkqK
__
Impact of parasitic infection on human gut ecology and immune regulations, Translational Medicine Communications -
https://archive.ph/iRG9U
__
Protease - Wikipedia -
https://archive.ph/52NDP
__
#countryvideo #Molnupiravir #putrification #parasites
(For Educational & Informative Purposes Only. Not Medical Advice. Please Consult A Qualified Health Care Provider.)

Both #Paxlovid and #molnupiravir reduce death in the short-term (1 month) and longer-term (6 months) for high-risk veterans (VA cohort). Paxlovid also showed a reduction in hospitalization rates.

#TWiVTLDR 8/

Don’t let the rainbow fool you. #Merck is currently:
1) advocating for multiple doses of #gardasil when one is sufficient
2) promoting #molnupiravir despite its ineffectiveness and risks to both patients and global health
3) suing to block #medicare from negotiating drug prices

(2) #MOLNUPIRAVIR (MOV). Merck obtained emergency approval for MOV in December 2021 — just barely the first oral antiviral against COVID-19.

But MOV works by causing viral mutations, the raw material for new variants of concern. 5/12

''Conclusion: #Nirmatrelvir–ritonavir was effective in reducing 30-day #hospitalization and #death. #Molnupiravir was associated with a benefit for 30-day mortality but not hospitalization. Further reductions in mortality from 31 to 180 days were observed with both antivirals.''

Effectiveness of #COVID-19 #Treatment With #Nirmatrelvir–Ritonavir or #Molnupiravir Among #US #Veterans: Target #Trial #Emulation Studies With One-Month and Six-Month Outcomes, Ann Intern Med., https://doi.org/10.7326/M22-3565

#Molnupiravir Use and 30-Day #Hospitalizations or #Death in Previously Uninfected Non-hospitalized High-risk Population with #COVID-19 https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad195/7187858?rss=1

COVID patients living in Hong Kong nursing homes given oral #antivirals reduced their hospitalization risk by A LOT. Interestingly, #molnupiravir performed better in this study than others. Dr. Griffin surmised it was probably because you could get a faster #COVID diagnosis and treatment in a nursing home. (Like all antivirals, you shouldn’t wait to get it, you should take it as soon as you can.) 10/

#TWiVTLDR

Evidence that oral antivirals have a beneficial impact on #COVID19 in high-risk patients. #nirmatrelvir #molnupiravir #Paxlovid

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804227

https://www.bmj.com/content/381/bmj-2022-074572 “In people with #SARSCoV2 infection and at least one risk factor for progression to severe #covid19, compared with no treatment, #molnupiravir use within five days of infection was associated with reduced risk of #PASC in people who had not received a covid-19 #vaccine, had received one or two vaccine doses, and had received a #booster dose, and in those with primary SARS-CoV-2 infection and #reinfection.”

#Covid19. AIFA sospende l’antivirale #molnupiravir: “No a problemi di sicurezza, ma mancanza benefici”

📌 La decisione dell'Agenzia italiana del farmaco segue il parere negativo del Chmp dell'Ema del 24 febbraio scorso: mancata dimostrazione di benefici in termini di riduzione della mortalità e dei ricoveri ospedalieri.

http://www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=111945

In New Zealand the Covid anti-viral Molnupiravir has proved only half as effective as Paxlovid, so it's off the menu.

https://www.stuff.co.nz/national/health/coronavirus/131447503/health-officials-decided-a-covid19-antiviral-should-no-longer-be-used-why-didnt-prescribers-know

#Covid #AntiVirals #Molnupiravir #Paxlovid #NZ

#IDMastodon #Clinicalinvestigation @bmj_latest @zalaly
The findings of this emulation of a randomized target trial suggest that #molnupiravir might have reduced hospital admission or death at 30 days in adults with #SarsCoV2 infection in the community during the recent #omicron predominant era who were at high risk of progression to severe #COVID19 and eligible for treatments
https://www.bmj.com/content/380/bmj-2022-072705

On #molnupiravir risks, the US #FDA is wrong & @michaelzlin is right.

Example: they confuse mutation and selection. Molnupiravir — unlike other drugs, antibodies & immunity — specifically works by causing mutations, not merely selecting them.

Remember at the Nov. 2021 FDA meeting, no other oral antivirals were yet available for COVID.

The vote was 13 YES / 10 NO, with some 'YES's noting that molnupiravir should be re-considered after other drugs available.

FDA doc: https://www.fda.gov/media/165856/download

On #molnupiravir risks, the US #FDA is wrong & @michaelzlin is right.

Example: their materials confuse mutation and selection. Molnupiravir — unlike other drugs, antibodies & immunity — specifically works by causing mutations, not merely selecting them.

Remember at the Nov. 2021 FDA meeting, no other oral antivirals were yet available for COVID.

The vote was a close 13 YES / 10 NO, with some 'YES's noting that, given risks, molnupiravir should be re-considered after other drugs available.

Das einst vielversprechende #Covid-Therapeutikum #Molnupiravir wird wohl abdanken. Die #EMA hat die Marktzulassung zurückgezogen.
http://docc.hk/td68up